We provide you with 20 years of free, institutional-grade data for XGN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of XGN. Explore the full financial landscape of XGN stock.
| Reported Date | CIK | Ticker | Type |
|---|
Exagen Inc(NASDAQ:XGN) 
Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of complex autoimmun...
Website: http://www.exagen.com
Founded: 2002
IPO Price: $14 (Sep 19, 2019)
Full Time Employees: 153
CEO: Fortunato Ron Rocca
Sector: Healthcare
Industry: Diagnostics & Research
The information provided in this report about XGN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.